Advanced Renal Cell Carcinoma Treatment Market Size & Share, by Treatment (Biologics, Radiation Therapy, Chemotherapy, Hormone, Vaccine Therapy); Route of Administration (Parenteral, Oral); End-user (Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3895
  • Published Date: Mar 02, 2023
  • Report Format: PDF, PPT

Companies Dominating the Advanced Renal Cell Carcinoma Treatment Landscape

top-features-companies
    • Ono Pharmaceutical Co., Ltd.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Novartis AG
    • Merck & Co., Inc.
    • Eisai Co., Ltd.
    • Chugai Pharmaceutical Co., Ltd.
    • Bristol Myers Squibb Company
    • Bayer AG
    • Pfizer Inc.
    • AbbVie Inc.
    • Teva Pharmaceuticals Industries Ltd.

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Bristol Myers Squibb Company and Exelixis, Inc. reported three-year follow-up results from the Phase 3 CheckMate-9ER trial. Compared to sunitinib, Opdivo (nivolumab) and CABOMETYX (cabozantinib) have demonstrated sustained survival and response rates when used as a first-line treatment for advanced renal cell carcinoma (RCC).

  • Merck & Co., Inc’s anti-PD-1 therapy KEYTRUDA has been approved by FDA for use as adjuvant therapy in patients with renal cell carcinoma (RCC) at intermediate-high or high recurrence risk following nephrectomy, or following nephrectomy and metastatic resection.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3895
  • Published Date: Mar 02, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Growing proportion of geriatric population, worldwide increasing ratio of smoking, and an upsurge in hypertension are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023-2035.

Dearth of technological innovations in genome sequencing in emerging nations, and extreme cost of treatment of renal cell carcinoma are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Ono Pharmaceutical Co., Ltd., Novartis AG, Merck & Co., Inc., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Bayer AG, Pfizer Inc., AbbVie Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment, route of administration, end-user, and by region.

The biologics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying